Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial is a research paper published in Cancer (2020). On theSindex it has a DataRank of 1.2. It has been cited 38 times, with 34 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.550
From this paper's citation signal
Citation Network Contribution
0.697
From 30 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 34 citers.
National Institutes of Health
Grant: NIH P30 Cancer Center Support Grant (P30 CA008748)
NCI NIH HHS
Grant: P30 CA008748
Fundação para a Ciência e a Tecnologia, I.P.
Grant: PTDC/CCI-INF/6762/2020
MS3: New foundations for micro-services and serverless systems
Novartis Pharma
Novartis
Novartis Pharma
FWCI
2.63
Citation Percentile
0.9%
Influential Citations
3
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals